APR Applied Pharma Research Introduces SwitzAge®: The First 100% Swiss Made Nutraceutical Product Line, Developed to Empower Adult Vitality
APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products, is proud to announce the reinforcement of its consumer products portfolio with SwitzAge®, an innovative range of nutraceuticals, 100% Swiss made, specifically created to meet adult people well-being needs.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170731005481/en/
SwitzAge®, the first 100% Swiss made Nutraceutical product line by APR (Photo: APR Applied Pharma Research s.a.)
Life expectancy has been globally growing in the last decades thanks to
the overall improvement of life quality standards and the so-called
Generation X is having a transformative impact on society. By 2050, the
number of over 50s worldwide is projected to double to nearly 3.2
billion people. These consumers are transforming what it means to be
older in terms of lifestyle and aim for an overall improvement of their
vitality, thus being more conscious of their diet and combing it with
the consumption of specific food supplements.
Asia-Pacific countries, in particular, where adult people account for almost 30% of the population, seem to drive the growth of the global food supplements market with an expected CAGR of 9.1% in the next five years, thus generating nearly half of the whole market, estimated around 84 USD billion, by 2020.
The SwitzAge® project has been specifically designed to match the
increasing demand for high-quality food supplements tailored on adult
people health needs.
SwitzAge® was inspired from a holistic approach focused on the specific physiological needs of man and lady for a balanced well-being of body and mind along the ageing natural course.
Each SwitzAge® product is the result of the Swiss high-quality
pharmaceutical research applied to healthy ageing. In particular,
products formulations contain a balanced mix of active ingredients
- vitamins, minerals and functional extracts, accurately selected
and controlled along the production process according to highest Swiss
quality standards. On the other side, SwitzAge® formulations are
compliant with European, Swiss and current Chinese food supplement
regulations, thus ensuring a favourable tolerability profile.
Moreover, they are lactose, sugar and gluten free and they all come in user-friendly pharmaceutical forms (mono-dose effervescent powder, chewable tablets and soft-gel capsules) for an easier administration, whilst offering the appropriate daily dosage in compliance with European and Swiss NRV recommendations.
SwitzAge® product line is currently made of 8 food supplements, that provide the right answers for body and mind enhancement, by improving physical energy extent as well as the overall balance in terms of memory, concentration and sleep quality, along with a proper differentiation per gender. Among the others, the range spans solutions for cardiovascular system efficiency and genitourinary well-being, for men, as well as for menopause hormonal swing regulation and skin anti-ageing for ladies.
"We are very proud - said Paolo Galfetti, CEO and Co-Founder of APR - to offer this new business opportunity to potential partners who are ready to exploit the increasing growth of the food supplement market addressed to adult and mature people needs. Seizing the global trend towards healthy ageing, SwitzAge® is the first range of scientific proven solutions which aims at enhancing adult and mature people quality of life, enabling their physical, social and mental well-being.”
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
Joensuu City Challenge – International Competition for Innovative SMEs Opened15.12.2017 08:24 | Pressemelding
City of Joensuu, Finland, has announced an international competition in which 200,000 euros will be used for innovative pilot projects in the city centre. Joensuu has defined four city platforms on which companies or other interested organizations are invited to present innovative proposals. The winning proposals will be implemented as pilot projects in Joensuu. The deadline for the proposals is 18th March 2018. The implementation phase of the proposals should be carried out by May 2019. Competition information is provided in English, and proposals can be made in English and Finnish. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005170/en/ Joensuu City Challenge - International Competition for Innovative SMEs Opened (Photo: Business Wire) The four challenges for which solutions are sought are v
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom